SCHEMBL864031

SCHEMBL864031

CC(Nc1ncnc(N)n1)c1cc2cccc(Cl)c2nc1NCC(C)(C)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 5/20 0.46
LMNA P02545 1/20 0.36
AURKA O14965 1/20 0.34
RPS6KB1 P23443 1/20 0.34
AURKB Q96GD4 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
CCNE1 P24864 2/20 0.33
CDK2 P24941 2/20 0.33
CDK7 P50613 2/20 0.33
CCNH P51946 2/20 0.33
CDK5 Q00535 2/20 0.33
CDK5R1 Q15078 2/20 0.33
CCNT1 O60563 1/20 0.33
CDK9 P50750 1/20 0.33
EGFR P00533 3/20 0.32
PIK3CG P48736 1/20 0.32
MAPK1 P28482 2/20 0.31
KRAS P01116 2/20 0.31
SOS1 Q07889 1/20 0.31
KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL864030 1.00 PIK3CD (0.46) PIK3CDLMNAAURKARPS6KB1AURKB
SCHEMBL864075 0.90 PIK3CD (0.41) PIK3CDAURKARPS6KB1AURKBCCNE1
SCHEMBL864074 0.90 PIK3CD (0.41) PIK3CDAURKARPS6KB1AURKBCCNE1
SCHEMBL863392 0.87 PIK3CD (0.42) PIK3CDCCNE1CDK2CDK7CCNH
SCHEMBL863393 0.87 PIK3CD (0.42) PIK3CDCCNE1CDK2CDK7CCNH
SCHEMBL864025 0.87 PIK3CD (0.45) PIK3CDLMNAAURKARPS6KB1AURKB
SCHEMBL864024 0.87 PIK3CD (0.45) PIK3CDLMNAAURKARPS6KB1AURKB
SCHEMBL15184786 0.84 PIK3CD (0.49) PIK3CDLMNAAURKARPS6KB1AURKB
SCHEMBL865367 0.84 PIK3CD (0.43) PIK3CDLMNAAURKARPS6KB1AURKB
SCHEMBL865366 0.84 PIK3CD (0.43) PIK3CDLMNAAURKARPS6KB1AURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8513284-B2 Fused pyridine and pyrazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2013-08-20 US disclosed
US-20120077815-A1 Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors UCB PHARMA S.A. (BE) 2012-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077815-A1 Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors PDPK1, PDXK, PIK3CA PIK3CD 14/4885LMNA 4619/4885AURKA 284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.